SEATTLE, Sept. 10, 2013 /PRNewswire/ -- So many advances have been made in the treatment of breast cancer that one has to wonder at its still stubbornly high rate, and the fact that it is still a leading cause of death in women. Catching the disease in its earliest stages through timely screening is inarguably a key factor, or perhaps even the key factor, in survival. At that point, not only can the cancerous cells be readily removed, but lifestyle changes can also be put in place to help prevent a recurrence.
As a woman gets older her risk does rise, but age is just one factor. A variety of lifestyle factors and heredity factorsincluding a family history of breast cancer or having the BRCA mutationcan also play a role.
According to materials published by the Mayo Clinic, mammography is not reliable for women with dense breast tissue. The screening can miss something or present a false positive, which could lead to unnecessary surgery, chemotherapy and radiation. Wouldn’t it be wonderful to have another screening option for women with dense breast tissuea test that could also detect precancerous signals?
The great news is that there is just such a simple and efficacious test that can fulfill all the above criteria. And yes, it also can provide vital early detection of precancerous conditions that may progress to cancer, and before cancer can be detected by mammography. This remarkable innovation is called the ForeCYTE Breast Health Test, and is available from the National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., based in Seattle, Washington.
“Just as the Pap smear reduced cervical cancer rates by more than 70 percent, becoming the most successful screening test in medicine, our goal is to similarly reduce the incidence of breast cancer through early detection of precursor changes that can lead to breast cancer,” says Dr. Steven C. Quay, Chairman, CEO and President of Atossa Genetics and inventor of the ForeCYTE Breast Health Test.
The test collects and analyzes individual cells from a small sample of fluid collected from each breast, and can provide vital early detection of cancer or precancerous conditions. No invasive biopsy needles or open surgical incisions are used.
Validation of the safety and effectiveness of the testing system was published in an article in the August 2013 issue of Advances in Bioscience and Biotechnology. The publication described a recent clinical study of Atossa’s Class II medical biopsy device, the Mammary Aspirate Specimen Cytology Test (MASCT) System, designed for use in a clinical setting for the collection of mammary aspirate specimens for laboratory testing. The results of the study showed that the test was “comfortable, safe and effective in the collection of nipple fluid for laboratory testing,” reports Dr. Quay.
More information on the ForeCYTE Breast Health Test and how to determine your risk for breast cancer, go to www.atossagenetics.com.
Media Contact: Laura Radocaj, Dian Griesel Int’l. 212.825.3210
SOURCE Atossa Genetics
Help employers find you! Check out all the jobs and post your resume.
